How has artificial intelligence impacted COVID-19 drug repurposing and what lessons have we learned?

E Sila Ozdemir; Srivathsan V Ranganathan; Ruth Nussinov

doi:10.1080/17460441.2022.2128333

How has artificial intelligence impacted COVID-19 drug repurposing and what lessons have we learned?

Expert Opin Drug Discov. 2022 Oct;17(10):1061-1065. doi: 10.1080/17460441.2022.2128333. Epub 2022 Sep 26.

Authors

E Sila Ozdemir¹, Srivathsan V Ranganathan¹, Ruth Nussinov^{2

3}

Affiliations

¹ Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
² Cancer Innovation Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA.
³ Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

PMID: 36154343
DOI: 10.1080/17460441.2022.2128333

No abstract available

Keywords: COVID-19; Drug repurposing; artificial intelligence; computational biology; knowledge graph; machine learning; personalized treatment; precision medicine.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural

MeSH terms

Algorithms
Artificial Intelligence*
COVID-19 Drug Treatment*
Drug Repositioning
Humans
Precision Medicine